NasdaqGS - Nasdaq Real Time Price USD

CytomX Therapeutics, Inc. (CTMX)

Compare
1.0900 -0.0100 (-0.91%)
At close: December 20 at 4:00:02 PM EST
1.0798 -0.01 (-0.94%)
After hours: December 20 at 5:17:01 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
126,617.0000
101,214.0000
53,163.0000
37,312.0000
68,427.0000
Operating Expense
119,907.0000
107,698.0000
154,498.0000
153,354.0000
148,967.0000
Operating Income
6,710.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
Net Non Operating Interest Income Expense
8,361.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
Other Income Expense
-10.0000
-30.0000
340.0000
-83.0000
-27.0000
Pretax Income
15,061.0000
3,323.0000
-99,317.0000
-115,870.0000
-78,731.0000
Tax Provision
1,231.0000
3,892.0000
--
--
-13,911.0000
Net Income Common Stockholders
13,830.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Diluted NI Available to Com Stockholders
13,830.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Basic EPS
0.16
-0.01
-1.51
-1.30
-1.40
Diluted EPS
0.16
-0.01
-1.51
-1.30
-1.40
Basic Average Shares
83,392.9820
73,808.2370
65,739.8440
64,146.8480
46,145.5630
Diluted Average Shares
83,710.7940
73,808.2370
65,739.8440
64,146.8480
46,145.5630
Total Operating Income as Reported
6,710.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
Total Expenses
119,907.0000
107,698.0000
154,498.0000
153,354.0000
148,967.0000
Net Income from Continuing & Discontinued Operation
13,830.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Normalized Income
13,830.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Interest Income
8,361.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
Net Interest Income
8,361.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
EBIT
6,710.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
EBITDA
8,551.0000
-4,309.0000
-98,892.0000
-113,336.0000
-77,967.0000
Reconciled Depreciation
1,841.0000
2,175.0000
2,443.0000
2,706.0000
2,573.0000
Net Income from Continuing Operation Net Minority Interest
13,830.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Normalized EBITDA
8,551.0000
-4,309.0000
-98,892.0000
-113,336.0000
-77,967.0000
Tax Rate for Calcs
0.0001
0.0002
--
--
0.0002
12/31/2020 - 10/8/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SPRO Spero Therapeutics, Inc.
0.9551
-4.30%
 
ASMB Assembly Biosciences, Inc.
15.21
-3.80%
 
NXTC NextCure, Inc.
0.9700
+2.11%
 
MRSN Mersana Therapeutics, Inc.
1.6000
-8.05%
 
HLVX HilleVax, Inc.
1.8600
+1.64%
 
BOLT Bolt Biotherapeutics, Inc.
0.5000
-0.70%
 
AADI Aadi Bioscience, Inc.
3.3900
+46.12%
 
AFMD Affimed N.V.
1.1900
+0.85%
 
IKNA Ikena Oncology, Inc.
1.5500
-3.73%
 
CLRB Cellectar Biosciences, Inc.
0.2350
-1.26%